ACLARUBICIN
Aclarubicin is an anthracycline antineoplastic agent that intercalates into DNA and inhibits topoisomerase II, preventing replication and transcription. It is used in acute myeloid leukemia treatment. Advantages include strong cytotoxic activity and lower cardiotoxicity relative to traditional anthracyclines. Risks include bone marrow suppression, nausea, vomiting, alopecia, and increased infection susceptibility, necessitating controlled dosing and patient monitoring. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of action
Aclarubicin is an anthracycline antitumour antibiotic closely related to aclacinomycin A. It acts by intercalating into DNA, inhibiting topoisomerase II and inducing DNA strand breaks and apoptosis in rapidly proliferating cells.
Benefits and advantages
Aclarubicin has been employed in regimens for acute leukaemias and certain lymphomas. Its structural modifications relative to doxorubicin and daunorubicin confer distinctive pharmacokinetic and toxicity profiles, which can be advantageous in specific patient populations.
Side effects and risks
Key toxicities include myelosuppression, mucositis, alopecia and potential cumulative cardiotoxicity. Hypersensitivity reactions and severe local damage after extravasation are additional concerns. Because of its potent cytotoxicity, this API must be handled exclusively in facilities equipped for safe manipulation of antineoplastic agents.
Professional use only. Supplied exclusively to licensed oncology institutions and manufacturers.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C42H53NO15 |
|---|---|
| Molecular Weight | 811.9 g/mol |
| CAS Number | 57576-44-0 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | aclarubicin; Aclacinomycin A; 57576-44-0; Aclarubicine; Aclarubicinum |
| IUPAC/Chemical Name | methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate |
| InChl Key | USZYSDMBJDPRIF-SVEJIMAYSA-N |
| InChl Code | InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
